Proactive news highlights: Base Resources, Galileo Resources, ImmuPharma, Sound Energy and more...
Daily round up of the day's news headlines from Proactive Investors.
Company
ImmuPharma PLC
LON:IMM
ImmuPharma PLC is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides. The company is dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on autoimmunity/inflammation and anti-infectives.
306 stories · page 14 of 16
Immupharma to recruit patients from Mauritius
The request to open a new site came directly from the government following a visit to the island nation by the drug’s inventor, professor Sylviane Muller.
Archive
Brokers: Barclays bullish on financial services
The bank has picked out several banking and financial stocks that it likes the look of, although Barclays has had its own stock downgraded by UBS
Proactive news highlights, including SolGold, W Resources and Challenger Acquisitions
A mixed news bag but small cap miners appeared to be out in force
Immupharma drug has billion dollar potential - Northland
It is a potential blockbuster, said the broker, which targets 171p for the share.
Immupharma moves forward with Lupus drug trials
Drug company said it had started dosing Lupus sufferers with Lupuzor
Archive
Small caps highlights: Aim stocks largely dodge blue-chip blues
Take Aim. London’s growth stocks have been immune to the negativity dogging the market for blue-chip shares.
Shot in the arm for ImmuPharma as shares spike 67%
Up more 67% in last five trading sessions it has been on the rampage since it was revealed that Alto Invest had taken its stake to 4.15%.
Blue-chip shares slide while Aim stocks thrive
The FTSE 100 surrendered all of May's gains to close 10 points down on the month
Small-cap pharma stocks rise but FTSE 100 Index treads water
The FTSE 100 Index trod water as traders shrugged off mixed economic data from the continent
Proactive news highlights: Diamondcorp, Forbidden Technologies, Gemfields,..
ITM Power announced that London's first hydrogen refuelling station is to open next week, Westminster Group awaits the arrival of the Sierra Princess and Deltex Medical reconfigures its probe tip.
ImmuPharma has its eye on the prize
"ImmuPharma is focused on ensuring the successful development of the late stage clinical development of Lupuzor through its pivotal phase III trial,” chairman Tim McCarthy told investors.
Sainsbury's results put UK retail under spotlight again
As if the UK retail sector hadn't had enough coverage last week, it's now the turn of Sainsbury's....
Hopes rise for AIM drug breakthroughs
A trio of AIM companies are putting potential new drugs through phase three trials